Related Experiment Video
Updated: May 15, 2026
A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
Published on: November 14, 2014
Comparative study of biological activity of four botulinum toxin type A preparations in mice
Myung Eun Chung1, Dae Heon Song, Joo Hyun Park
1Department of Rehabilitation Medicine, St. Paul's Hospital, College of Medicine, Catholic University of Korea, Seoul, Korea.
Background:
Units of available botulinum toxin preparations are not interchangeable, and the dose-conversion ratios between such preparations remain controversial.
Objective:
To compare the efficacy and safety of four botulinum toxin type A preparations.
Materials And Methods:
Murine gastrocnemius compound muscle action potentials (CMAPs) were recorded before and after injecting the four botulinum toxin preparations (onabotulinumtoxinA, abobotulinumtoxinA, new botulinum toxin, and incobotulinumtoxinA).
Results:
In all preparations, CMAP amplitudes decreased until 4 days after receiving the injection and then gradually recovered. On postinjection day 84, the amplitudes returned to baseline in all groups except the high-dose groups. CMAP amplitude in the contralateral limb also decreased up to postinjection days 4 to 7 and then gradually returned to baseline by postinjection day 28.
Conclusion:
The dose-conversion ratio between onabotulinumtoxinA and abobotulinumtoxinA was determined to be 1:2.6; previous reports of 1:3 were considered too high. A dose-conversion ratio between onabotulinumtoxinA and new botulinum toxin of 1:1 was deemed appropriate. OnabotulinumtoxinA and incobotulinumtoxinA demonstrated a dose-conversion ratio of 1:1.07. The efficacy of incobotulinumtoxinA was slightly lower than that of onabotulinumtoxinA. These dose-conversion ratios are applicable solely from an efficacy standpoint and not for safety. This study was conducted in mice, so it may not translate perfectly to human applications.
Insights
This study determined dose-conversion ratios for four botulinum toxin type A preparations in mice. OnabotulinumtoxinA to abobotulinumtoxinA ratio was 1:2.6, and 1:1 for new botulinum toxin and incobotulinumtoxinA.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Botulinum toxin type A preparations are not interchangeable.
- Dose-conversion ratios between different botulinum toxin preparations are debated.
Purpose of the Study:
- To compare the efficacy and safety of four botulinum toxin type A preparations.
- To establish accurate dose-conversion ratios for clinical use.
Main Methods:
- Murine gastrocnemius compound muscle action potentials (CMAPs) were recorded.
- Four botulinum toxin type A preparations were injected: onabotulinumtoxinA, abobotulinumtoxinA, new botulinum toxin, and incobotulinumtoxinA.
Main Results:
- CMAP amplitudes decreased post-injection, returning to baseline by day 84 in most groups.
- Contralateral limb CMAP amplitudes also decreased and recovered within 28 days.
- Efficacy varied slightly between preparations, with incobotulinumtoxinA showing slightly lower efficacy than onabotulinumtoxinA.
Conclusions:
- Established dose-conversion ratios: onabotulinumtoxinA:abobotulinumtoxinA (1:2.6), onabotulinumtoxinA:new botulinum toxin (1:1), and onabotulinumtoxinA:incobotulinumtoxinA (1:1.07).
- These ratios are efficacy-based and may not apply to safety.
- Findings in mice may not directly translate to human applications.
More Related Videos
12:25Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
10:30A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
